Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Your price includes the physician consultation, prescription, medication, and free shipping
Outcomes were compared by GLP-1 RA agent, dosage, indication, and persistent coverage with the medication
Milliken BT, Elfers C, Chepurny OG, Chichura KS, Sweet IR, Borner T, et al
Some had incorrect concentrations
Formulation and Delivery Comparison# Afamelanotide (Scenesse)# The pharmaceutical formulation uses a controlled-release bioresorbable implant: Melanotan-1 (Research Peptide)# The research peptide version is sold as lyophilized powder: Mechanism of Action# Both afamelanotide and melanotan-1 share the same mechanism: MC1R binding : The peptide binds to melanocortin-1 receptors (MC1R) on melanocytes with high affinity and longer duration than native alpha-MSH Adenylyl cyclase activation : MC1R activation stimulates adenylyl cyclase, increasing intracellular cAMP PKA/CREB pathway : cAMP activates protein kinase A, which phosphorylates CREB transcription factor MITF induction : CREB activates the MITF gene, the master regulator of melanocyte function Eumelanin synthesis : MITF upregulates tyrosinase and other enzymes in the eumelanin biosynthetic pathway Photoprotection : Increased eumelanin provides UV absorption and free radical scavenging The key distinction from alpha-MSH is the substitutions at positions 4 (norleucine replaces methionine) and 7 (D-phenylalanine replaces L-phenylalanine), which increase metabolic stability from minutes to hours
